Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05148299 · ClinicalTrials.gov registry record · Phase 2
A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation
A Phase 2 study, sponsored by Swedish Orphan Biovitrum.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT05148299 is a Phase 2 study that has completed, run by Swedish Orphan Biovitrum. The registered enrollment target is 12 participants.
The verdict
NCT05148299, a Phase 2 study, has completed, sponsored by Swedish Orphan Biovitrum.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of the study was to assess pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of pegcetacoplan in patients with TA-TMA after HSCT.
Interventions
- DRUG Pegcetacoplan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2024-12-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05148299
The ClinicalTrials.gov registry entry for NCT05148299 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Swedish Orphan Biovitrum, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegcetacoplan is the first listed.
NCT05148299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05148299 about?
NCT05148299 is a clinical study titled "A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation". The purpose of the study was to assess pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of pegcetacoplan in patients with TA-TMA after HSCT.
What is the current status of trial NCT05148299?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2022-02-01. Estimated completion is 2024-12-08.
What interventions are being tested in trial NCT05148299?
The interventions under investigation include: Pegcetacoplan (DRUG).
Who is sponsoring clinical trial NCT05148299?
This trial is sponsored by Swedish Orphan Biovitrum, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.